AU2017388466B2 - Heteroaryl compounds and their use - Google Patents

Heteroaryl compounds and their use Download PDF

Info

Publication number
AU2017388466B2
AU2017388466B2 AU2017388466A AU2017388466A AU2017388466B2 AU 2017388466 B2 AU2017388466 B2 AU 2017388466B2 AU 2017388466 A AU2017388466 A AU 2017388466A AU 2017388466 A AU2017388466 A AU 2017388466A AU 2017388466 B2 AU2017388466 B2 AU 2017388466B2
Authority
AU
Australia
Prior art keywords
alkyl
group
membered
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017388466A
Other languages
English (en)
Other versions
AU2017388466A1 (en
Inventor
Xavier BARRIL ALONSO
Elena CUBERO JORDÀ
Ana Maria GARCÍA COLLAZO
Marc REVÉS VILAPLANA
Richard Spurring Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minoryx Therapeutics SL
Original Assignee
Minoryx Therapeutics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics SL filed Critical Minoryx Therapeutics SL
Publication of AU2017388466A1 publication Critical patent/AU2017388466A1/en
Application granted granted Critical
Publication of AU2017388466B2 publication Critical patent/AU2017388466B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
AU2017388466A 2016-12-29 2017-12-28 Heteroaryl compounds and their use Ceased AU2017388466B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382672.0 2016-12-29
EP16382672 2016-12-29
PCT/IB2017/058477 WO2018122775A1 (en) 2016-12-29 2017-12-28 Heteroaryl compounds and their use

Publications (2)

Publication Number Publication Date
AU2017388466A1 AU2017388466A1 (en) 2019-07-25
AU2017388466B2 true AU2017388466B2 (en) 2022-04-28

Family

ID=57708486

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017388466A Ceased AU2017388466B2 (en) 2016-12-29 2017-12-28 Heteroaryl compounds and their use

Country Status (9)

Country Link
US (2) US11174242B2 (https=)
EP (1) EP3562811B1 (https=)
JP (1) JP7171057B2 (https=)
CN (1) CN110325516A (https=)
AU (1) AU2017388466B2 (https=)
BR (1) BR112019013571A2 (https=)
CA (1) CA3048357A1 (https=)
IL (1) IL267626B2 (https=)
WO (1) WO2018122775A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11174242B2 (en) 2016-12-29 2021-11-16 Minoryx Therapeutics S.L. Heteroaryl compounds and their use
WO2020104578A2 (en) * 2018-11-21 2020-05-28 University Of Copenhagen Modulators of free fatty acid receptor 1 and their use for treatment of diseases
AU2020394602A1 (en) * 2019-11-25 2022-06-30 Gt Gain Therapeutics Sa Heteroaryl compounds and therapeutic uses thereof in conditions associated with the alteration of the activity of beta-glucocerebrosidase
US20230103407A1 (en) * 2020-03-10 2023-04-06 University Of Cincinnati Materials and methods for the treatment of gaucher disease
CN117659017A (zh) * 2022-08-25 2024-03-08 北京华益健康药物研究中心 Trpml1/2调节剂化合物、药物组合物及其制备方法和应用
EP4676474A2 (en) * 2023-03-24 2026-01-14 Purdue Research Foundation Symmetric aminoindole-linked triazine for a dual effect on alpha-synuclein and tau isoform 2n4r fibrillization

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019469A1 (en) * 2011-08-01 2013-02-07 The Wistar Institute Microrna modulators and method for identifying and using the same
WO2014064118A1 (en) * 2012-10-24 2014-05-01 Glucox Biotech Ab Triazine derivatives for the treatment of conditions associated with nicotinamide adenine dinucleotide phosphate oxidase

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL350050A1 (en) 1999-01-22 2002-10-21 Elan Pharm Inc Acyl derivatives which treat vla-4 related disorders
IL156315A0 (en) 2000-12-07 2004-01-04 Cv Therapeutics Inc Abca-1 elevating compounds
US20030078271A1 (en) 2001-01-31 2003-04-24 Blackburn Thomas P. Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
BR0206844A (pt) * 2001-01-31 2005-07-12 Synaptic Pharma Corp Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos
JP4469179B2 (ja) 2002-01-23 2010-05-26 バイエル ファーマセチカル コーポレーション Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体
ES2273047T3 (es) * 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
CN1199946C (zh) 2002-10-29 2005-05-04 无锡杰西医药科技有限公司 一种特异性吲哚类化合物及制备方法与其在治疗和预防癌症等疾病中的应用
KR20080004585A (ko) 2005-04-08 2008-01-09 바이엘 파마슈티칼스 코포레이션 피리미딘 유도체 및 암의 치료에서의 이의 용도
US20090306038A1 (en) 2005-09-13 2009-12-10 Carceller Gonzalez Elena 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity
JP5337405B2 (ja) 2007-09-17 2013-11-06 ザ・ホスピタル・フォー・シック・チルドレン ゴーシェ病の治療方法
US8138356B2 (en) 2007-10-16 2012-03-20 Angiogeney, Inc. Chemical inhibitors of inhibitors of differentiation
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8119637B2 (en) * 2008-06-10 2012-02-21 Plexxikon Inc. Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor
WO2011049737A1 (en) 2009-10-19 2011-04-28 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating lysosomal storage disorders
WO2012035055A1 (en) * 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
AU2012231275A1 (en) 2011-03-18 2013-10-17 Genzyme Corporation Glucosylceramide synthase inhibitors
WO2012177997A1 (en) 2011-06-22 2012-12-27 The General Hospital Corporation Treatment of proteinopathies
WO2013059119A1 (en) 2011-10-17 2013-04-25 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
CA2868459A1 (en) 2012-03-27 2013-10-03 Amicus Therapeutics, Inc. Polymorphs of (3r,4r,5s)-5-(difluoromethyl)piperidine-3,4-diol fumarate and uses thereof
EP3027590A1 (en) 2013-07-31 2016-06-08 Minoryx Therapeutics S.L. Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof
US10738026B2 (en) * 2014-02-12 2020-08-11 Purdue Pharma L.P. Isoquinoline derivatives and use thereof
HRP20240644T1 (hr) 2014-11-06 2024-08-02 Bial-R&D Investments, S.A. Supstituirani pirazolo(1,5-a)pirimidini i njihova uporaba u liječenju medicinskih poremećaja
WO2016120808A1 (en) 2015-01-28 2016-08-04 Minoryx Therapeutics S.L. Heteroarylaminoisoquinolines, methods for their preparation and therapeutic uses thereof
US10173988B2 (en) 2015-02-16 2019-01-08 Glucox Biotech Ab N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine
CA2982769A1 (en) 2015-04-15 2016-10-20 Biomarin Pharmaceutical Inc. Methods for treating lysosomal storage disorders
US10308656B2 (en) 2015-08-18 2019-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of Ku70/80 and uses thereof
CN105412114A (zh) * 2015-12-11 2016-03-23 卢璐娇 6-{[4-(2-氟苯基)1-哌嗪基]甲基}-n-(萘基)-1,3,5-三嗪-2,4-二胺在制备血管生成抑制剂中的应用
US11174242B2 (en) 2016-12-29 2021-11-16 Minoryx Therapeutics S.L. Heteroaryl compounds and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019469A1 (en) * 2011-08-01 2013-02-07 The Wistar Institute Microrna modulators and method for identifying and using the same
WO2014064118A1 (en) * 2012-10-24 2014-05-01 Glucox Biotech Ab Triazine derivatives for the treatment of conditions associated with nicotinamide adenine dinucleotide phosphate oxidase

Also Published As

Publication number Publication date
CN110325516A (zh) 2019-10-11
US20190337922A1 (en) 2019-11-07
US11739072B2 (en) 2023-08-29
CA3048357A1 (en) 2018-07-05
WO2018122775A1 (en) 2018-07-05
JP2020504122A (ja) 2020-02-06
IL267626B1 (en) 2023-04-01
AU2017388466A1 (en) 2019-07-25
EP3562811A1 (en) 2019-11-06
US20220135535A1 (en) 2022-05-05
IL267626A (en) 2019-08-29
JP7171057B2 (ja) 2022-11-15
BR112019013571A2 (pt) 2020-01-07
US11174242B2 (en) 2021-11-16
EP3562811B1 (en) 2022-03-16
IL267626B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
AU2017388466B2 (en) Heteroaryl compounds and their use
JP4942486B2 (ja) 受容体チロシンキナーゼの阻害剤としてのピラゾール誘導体
AU2018286221B2 (en) Aminopyrimidine compound, preparation method therefor and use thereof
CA2681501A1 (en) Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
KR20230092958A (ko) Mas-관련 G-단백질 수용체 X2의 조절제 및 관련 생성물 및 이의 용도
EP3309160A1 (en) Pyrazolo[1,5-a]pyridine derivatives and methods of their use
JP2009532375A (ja) キナーゼ阻害剤
JP2023513794A (ja) Ｕｌｋ１／２の阻害剤およびその使用方法
WO2015014900A1 (en) Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof
JP7691753B2 (ja) ベータ－グルコセレブロシダーゼの活性の変質に関連する状態におけるヘテロアリール化合物およびその治療的使用
AU2017388300B2 (en) Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase
CA3158288C (en) Heteroaryl compounds and therapeutic uses thereof in conditions associated with the alteration of the activity of beta-glucocerebrosidase
HK40014139B (en) Heteroaryl compounds and their use
HK40014139A (en) Heteroaryl compounds and their use
JP2008510734A (ja) キナーゼ阻害剤
EA052781B1 (ru) Гетероарильные соединения и их терапевтическое применение при состояниях, связанных с изменением активности бета-глюкоцереброзидазы
HK40013599A (en) Heteroaryl compounds and their use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired